Multi-institutional Study of Osimertinib Dose-Optimization in Non-Small Cell Lung Cancer Patients with EGFR Activating Mutation Aged 70 Years or Older (‘MONEY’ Trial)
Japanese Journal of Clinical Oncology（2024）
Key words
osimertinib,dose-optimization,non-small cell lung cancer,epidermal growth factor receptor activating mutation,regression discontinuity design
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined